ArriVent BioPharma, Inc. Quarterly Operating Income (Loss) in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ArriVent BioPharma, Inc. quarterly Operating Income (Loss) history and growth rate from Q1 2023 to Q3 2024.
  • ArriVent BioPharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$24.2M, a 45% decline year-over-year.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$24.2M -$7.52M -45% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$25.7M -$3.11M -13.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$20.7M -$8.5M -69.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q3 2023 -$16.7M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$22.6M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$12.2M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.